NIPH Clinical Trials Search

Single and Multiple Dose Study of MK-2828 in Healthy Japanese Participants

Basic Information

Recruitment status	Pending
Health condition(s) or Problem(s) studied	Heart failure with preserved ejection fraction
Date of first enrollment	25/03/2026
Target sample size	32
Countries of recruitment
Study type	Interventional
Intervention(s)	Panel A: MK-2828 10mg or 80 mg single oral dose administration. Panel B: MK-2828 40 mg or 160 mg or less single oral dose administeration. Panel C: MK-6916 30 mg or less QD for 12 days multiple oral dose administration. Panel D: MK-6916 50 mg or less QD for 12 days multiple oral dose administration.

Outcome(s)

Primary Outcome	Adverse events, discontinuation of study intervention due to adverse event(s)
Secondary Outcome	Pharmacokineticks

Key inclusion & exclusion criteria

Age minimum	>= 24age old
Age maximum	<= 55age old
Gender	Both
Include criteria	Healthy male and female participants between the ages of 24 and 55 years
Exclude criteria	Has a history of clinically significant abnormalities or diseases